Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9

J D Jonkman-de Vries¹, J J Kettenes-van den Bosch, R E Henrar

¹Department of Pharmacy, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands.

|January 1, 1996

Abstract:

The pharmaceutical development of the investigational cytotoxic drug EO9 included the structural characterization of the bulk drug by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and infrared (IR) spectroscopy, and analytical characterization by high-performance liquid chromatography and ultraviolet/visible spectrophotometry. The presence of impurities in the bulk drug was investigated. The intermediates in the synthesis of EO9 were structurally characterized by NMR spectroscopy and MS, and analytically characterized by HPLC analysis with photodiode array (PDA) detection. All of the intermediates were below their limits of detection in EO9 bulk drug. The amounts of residual organic solvents were determined by gas chromatography. Methanol and ethanol were detected, but the amounts present did not exceed the limits as set in the United States Pharmacopeia XXII.

Related Experiment Videos

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9

Related Concept Videos

Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.

Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.

Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.

Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).

Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis.

First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.

Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification.

Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer.

Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence.

The Effect of Ceratonia siliqua (Carob) on Male Infertility: A Systematic Review and Meta-analysis of invitro and randomized controlled trials.

Design, Synthesis and Biophysical Characterisation of CPP-PNA Conjugates for Targeting Oncogenic microRNA-221.

The effects of fentanyl and dexmedetomidine on cardiorespiratory activity: implications for morbidity and mortality associated with adulterated fentanyl products.

Extraction, purification, characterization, and in vitro anticoagulant activity of polysaccharides from Cordyceps militaris.

Orphaned by an Evidentiary Standard: How Efficacy Review Emptied the Anabolic-Androgenic Steroid Market, and What Doping Control Inherited.

Effects of naringenin on superovulation in mice: evaluation of zygote and blastocyst development, histopathology, and molecular docking insights.

Related Experiment Videos

Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9

Abstract:

Related Concept Videos

Related Articles